contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


circio-holding-asa-key-events-and-financial-highlights-2h-2025-and-ytd-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Circio Holding

Oslo, 8 April 2026: Circio Holding ASA (the “Company”) hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well ...

<div class="mfn-preamble"><p><strong>Oslo, 8 April 2026: Circio Holding ASA (the “Company”) hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date 2026.</strong></p></div><div class="mfn-body"><p>Key highlights and events include:</p><ul><li>Up to 40-fold enhanced AAV expression in heart tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% boost over generation 3.2</li><li>New in vivo data post-period showing up to 50-fold enhanced circVec-AAV gene expression in eye</li><li>Fully funded feasibility study on circVec AAV gene therapy entered with a top 5 global pharmaceutical corporation</li><li>New research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR-Macrophage therapy)</li><li>Rights issue completed in Q1 2026 with more than 50% over-subscription, raising total gross proceeds of approximately NOK 68.6 million</li><li>Net cash balance as of 31 March 2026 of NOK 42 million</li><li>Abstract selected for oral presentation at the ASGCT annual meeting in Boston, May 2026</li></ul><p>More detailed information about key events and developments, as well as preliminary and unaudited financial information, including the Group's profit and loss for 2H2025 and net cash position as of 31 December 2025, and a going concern assessment can be found in the attached presentation.</p><p>The Annual Report for 2025 will be published on 15 April 2026.</p></div><div class="mfn-footer mfn-contacts mfn-a2287eff07eb"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Erik Digman Wiklund, CEO<br>Phone: +47 413 33 536<br>Email: <a href="mailto:erik.wiklund@circio.com" rel="noopener">erik.wiklund@circio.com</a></p><p>Lubor Gaal, CFO<br>Phone: +34 683 34 3811<br>Email: <a href="mailto:lubor.gaal@circio.com" rel="noopener">lubor.gaal@circio.com</a></p></div><div class="mfn-footer mfn-f39223047539"><p><strong class="mfn-heading-1">About Circio</strong><br><em><strong>Building circular RNA expression systems for enhanced gene and cell therapies</strong></em></p><p><em>Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.</em></p><p><em>Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&amp;D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-primary" href="https://storage.mfn.se/a12030ae-8eaa-4873-a61e-2475146bf908/key-events-and-financial-highlights-2h-2025-and-ytd-2026.pdf" rel="noopener">Key Events And Financial Highlights – 2H 2025 And YTD 2026</a></p></div>

Circio Holding ASA – Key events and financial highlights – 2H 2025 and YTD 2026

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up